NCI-H211 Cells

NCI-H211 is a human lung carcinoma cell line classified as non-small cell lung cancer (NSCLC). It was derived from an adult patient and is part of the panel of thoracic malignancy models developed through the NCI-Navy Medical Oncology Branch. The cell line demonstrates epithelial morphology and adherent growth behavior in vitro, making it suitable for monolayer culture systems. It is typically maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and incubated under standard conditions (37°C, 5% CO₂).

On a molecular level, NCI-H211 harbors mutations consistent with NSCLC pathogenesis. Specifically, it possesses an activating KRAS mutation, a hallmark of a subset of lung adenocarcinomas that drives oncogenic signaling through the MAPK and PI3K/AKT pathways. This mutation contributes to the cell line’s resistance to certain targeted therapies, particularly EGFR inhibitors, while simultaneously rendering it a useful model for studying KRAS-directed therapeutic strategies. Protein-level profiling studies, such as those using reverse-phase protein arrays (RPPA), have identified NCI-H211 among the KRAS-mutant lung cancer models with specific signaling dependencies, aiding in the identification of biomarkers and therapeutic targets.

NCI-H211 has been featured in large-scale proteomic and pharmacologic screens and has been used to evaluate drug sensitivities and protein expression patterns. These features make it an effective model for translational research focused on developing treatment approaches for KRAS-driven NSCLC and investigating resistance mechanisms associated with targeted and cytotoxic agents.